EGFR and non-small cell lung carcinoma: In conclusion, this study demonstrated that treatment with EGFR inhibitor-based combination therapies was associated with SD ≥6 months/PR in subtypes of heavily pretreated advanced NSCLC not traditionally associated with response to EGFR inhibitors, including 1 of 2 patients with a de novo EGFR-resistant mutation; 2 of 12 patients (17%) with an EGFR-sensitive mutation and secondary EGFR resistance after a period of initial response; 5 of 19 evaluable patients (26%) with EGFR wild-type disease; and, 1 of 3 evaluable patients (25%) with squamous cell carcinoma.